JP2009512719A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009512719A5 JP2009512719A5 JP2008536890A JP2008536890A JP2009512719A5 JP 2009512719 A5 JP2009512719 A5 JP 2009512719A5 JP 2008536890 A JP2008536890 A JP 2008536890A JP 2008536890 A JP2008536890 A JP 2008536890A JP 2009512719 A5 JP2009512719 A5 JP 2009512719A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkynyl
- cycloalkyl
- alkenyl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000753 cycloalkyl group Chemical group 0.000 claims 30
- 125000000623 heterocyclic group Chemical group 0.000 claims 27
- 125000003118 aryl group Chemical group 0.000 claims 24
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 24
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical group [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 17
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000001188 haloalkyl group Chemical group 0.000 claims 13
- 125000003342 alkenyl group Chemical group 0.000 claims 11
- 125000000304 alkynyl group Chemical group 0.000 claims 11
- 102000009058 Death Domain Receptors Human genes 0.000 claims 7
- 108010049207 Death Domain Receptors Proteins 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims 5
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims 5
- 108700012411 TNFSF10 Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000003607 modifier Substances 0.000 claims 5
- 230000002062 proliferating effect Effects 0.000 claims 5
- 229940044601 receptor agonist Drugs 0.000 claims 5
- 239000000018 receptor agonist Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000007801 affinity label Substances 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- 239000004305 biphenyl Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 102100032187 Androgen receptor Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102100038595 Estrogen receptor Human genes 0.000 claims 1
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 229940113306 Ligase inhibitor Drugs 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 claims 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 229940123468 Transferase inhibitor Drugs 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000037012 chymotrypsin-like activity Effects 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 239000004030 hiv protease inhibitor Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000000091 immunopotentiator Effects 0.000 claims 1
- 108010093036 interleukin receptors Proteins 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000000436 ligase inhibitor Substances 0.000 claims 1
- 229950001869 mapatumumab Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000036457 multidrug resistance Effects 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 102000027483 retinoid hormone receptors Human genes 0.000 claims 1
- 108091008679 retinoid hormone receptors Proteins 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 239000003558 transferase inhibitor Substances 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 0 C*(C)NC(N*C1CC1)=O Chemical compound C*(C)NC(N*C1CC1)=O 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72972705P | 2005-10-25 | 2005-10-25 | |
| US83066206P | 2006-07-14 | 2006-07-14 | |
| PCT/CA2006/001721 WO2007048224A1 (en) | 2005-10-25 | 2006-10-20 | Iap bir domain binding compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009512719A JP2009512719A (ja) | 2009-03-26 |
| JP2009512719A5 true JP2009512719A5 (enExample) | 2009-12-03 |
Family
ID=37965208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008536890A Pending JP2009512719A (ja) | 2005-10-25 | 2006-10-20 | Ｉａｐｂｉｒドメイン結合化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US7589118B2 (enExample) |
| EP (1) | EP1951698A4 (enExample) |
| JP (1) | JP2009512719A (enExample) |
| KR (1) | KR20080067357A (enExample) |
| AU (1) | AU2006308453B9 (enExample) |
| BR (1) | BRPI0617751A2 (enExample) |
| CA (1) | CA2564872C (enExample) |
| IL (1) | IL190936A0 (enExample) |
| RU (1) | RU2418807C2 (enExample) |
| WO (1) | WO2007048224A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5230865B2 (ja) | 2004-07-15 | 2013-07-10 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ結合性化合物 |
| ES2349110T5 (es) | 2004-12-20 | 2013-11-27 | Genentech, Inc. | Inhibidores de IAP derivados de pirrolidina |
| CN103083644B (zh) | 2005-02-25 | 2014-05-28 | 泰特拉洛吉克药业公司 | Iap二聚体抑制剂 |
| EP1883627B1 (en) * | 2005-05-18 | 2018-04-18 | Pharmascience Inc. | Bir domain binding compounds |
| US20100256046A1 (en) * | 2009-04-03 | 2010-10-07 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
| CA2564872C (en) | 2005-10-25 | 2010-12-21 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| RU2451025C2 (ru) | 2005-12-19 | 2012-05-20 | Дженентек, Инк. | Ингибиторы iap |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| MX2008012053A (es) * | 2006-03-21 | 2008-12-17 | Joyant Pharmaceuticals Inc | Promotores de apoptosis de molecula pequeña. |
| SG171682A1 (en) * | 2006-05-16 | 2011-06-29 | Aegera Therapeutics Inc | Iap bir domain binding compounds |
| US20100056495A1 (en) * | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| WO2008014238A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| AR064235A1 (es) * | 2006-07-24 | 2009-03-25 | Tetralogic Pharmaceuticals Cor | Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer |
| WO2008014240A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| EP2049563B1 (en) * | 2006-07-24 | 2014-03-12 | Tetralogic Pharmaceuticals Corporation | Dimeric iap antagonists |
| US20100144650A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| AU2008245447C1 (en) * | 2007-04-30 | 2014-11-20 | Genentech, Inc. | Inhibitors of IAP |
| WO2008137930A1 (en) * | 2007-05-07 | 2008-11-13 | Tetralogic Pharmaceuticals Corp. | TNFα GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS |
| US20100203012A1 (en) * | 2007-05-30 | 2010-08-12 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
| US20120141496A1 (en) * | 2007-12-17 | 2012-06-07 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
| CN101970457A (zh) * | 2008-01-11 | 2011-02-09 | 健泰科生物技术公司 | Iap抑制剂 |
| US20110117081A1 (en) * | 2008-05-05 | 2011-05-19 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
| US20110171171A1 (en) * | 2008-06-27 | 2011-07-14 | Aegera Therapeutics, Inc. | Bridged secondary amines and use thereof as iap bir domain binding compounds |
| EP2318395A4 (en) * | 2008-08-02 | 2011-10-26 | Genentech Inc | IPA INHIBITORS |
| US20100317593A1 (en) * | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| US8779280B2 (en) * | 2009-08-18 | 2014-07-15 | Lg Electronics Inc. | Solar cell and method of manufacturing the same |
| WO2011059763A2 (en) | 2009-10-28 | 2011-05-19 | Joyant Pharmaceuticals, Inc. | Dimeric smac mimetics |
| EP3263583A1 (en) | 2010-02-12 | 2018-01-03 | Pharmascience Inc. | Iap bir domain binding compounds |
| UY33236A (es) * | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| WO2011116286A2 (en) * | 2010-03-18 | 2011-09-22 | Innopharma, Llc | Stable bortezomib formulations |
| US8263578B2 (en) | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| US20140243276A1 (en) | 2011-09-30 | 2014-08-28 | Tetralogic Pharmaceuticals Corporation | Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer) |
| SG11201509525XA (en) | 2013-06-25 | 2016-01-28 | Inst Medical W & E Hall | Method of treating intracellular infection |
| US10300074B2 (en) | 2014-06-04 | 2019-05-28 | Sanford Burnham Prebys Medical Discovery Institute | Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| JP7515175B2 (ja) | 2018-07-31 | 2024-07-12 | ファイメクス株式会社 | 複素環化合物 |
| KR20220012844A (ko) * | 2019-04-05 | 2022-02-04 | 헤파진 테라퓨틱스 (에이치케이) 리미티드 | 아포토시스 단백질 억제제의 2가 길항제 |
| JP7764027B2 (ja) | 2019-07-31 | 2025-11-05 | ファイメクス株式会社 | 複素環化合物 |
| JP2023510426A (ja) | 2020-01-20 | 2023-03-13 | アストラゼネカ・アクチエボラーグ | 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤 |
| WO2024165017A1 (zh) * | 2023-02-08 | 2024-08-15 | 成都先导药物开发股份有限公司 | 杂环化合物及其用途 |
| KR102848239B1 (ko) * | 2023-04-13 | 2025-08-19 | 성신여자대학교 연구 산학협력단 | 비천연 아미노산을 포함하는 htra 표적 테트라펩타이드 프로브 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0680077B2 (ja) | 1985-02-08 | 1994-10-12 | サントリー株式会社 | プロリンエンドペプチダ−ゼインヒビタ−活性を有する新規ペプチド化合物 |
| US5750646A (en) * | 1987-09-24 | 1998-05-12 | The Administrators Of The Tulane Educational Fund | Bradykinin analogs with non-peptide bond |
| GB9016810D0 (en) | 1990-07-31 | 1990-09-12 | Wellcome Found | Peptides |
| JPH04208299A (ja) | 1990-11-30 | 1992-07-29 | Ajinomoto Co Inc | プロリルエンドペプチターゼ阻害ペプチド |
| US5387671A (en) | 1990-12-27 | 1995-02-07 | Abbott Laboratories | Hexa- and heptapeptide anaphylatoxin-receptor ligands |
| KR100213201B1 (ko) * | 1996-05-15 | 1999-08-02 | 윤종용 | 씨모스 트랜지스터 및 그 제조방법 |
| US6423689B1 (en) | 1997-12-22 | 2002-07-23 | Warner-Lambert Company | Peptidyl calcium channel blockers |
| RU2298547C2 (ru) | 1998-06-30 | 2007-05-10 | Ново Нордиск А/С | Соединения и фармацевтическая композиция, обладающие свойствами высвобождения гормона роста, способ стимуляции выделения гормона роста из гипофиза млекопитающего |
| US6110691A (en) | 2000-01-06 | 2000-08-29 | Board Of Regents, The University Of Texas System | Activators of caspases |
| US6608026B1 (en) | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
| AU2001293189A1 (en) | 2000-09-29 | 2002-04-08 | Trustees Of Princeton University | Compositions and methods for regulating apoptosis |
| US6992063B2 (en) | 2000-09-29 | 2006-01-31 | The Trustees Of Princeton University | Compositions and method for regulating apoptosis |
| WO2002030959A2 (en) | 2000-10-13 | 2002-04-18 | Abbott Laboratories | Peptides derived from smac (diablo) and methods of use therefor |
| MXPA03010762A (es) | 2001-05-31 | 2005-03-07 | Univ Princeton | Peptidos enlazantes de iap y ensayos para identificar los compuestos que enlazan el iap. |
| US20060258581A1 (en) | 2001-11-21 | 2006-11-16 | Reed John C | Methods and composition for derepressions of IAP-inhibited caspase |
| WO2003086470A2 (en) | 2002-04-17 | 2003-10-23 | Deutsches Krebsforschungszentrum | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| CN100384819C (zh) | 2002-07-02 | 2008-04-30 | 诺瓦提斯公司 | 与细胞凋亡蛋白抑制剂结合的smac蛋白的肽抑制剂 |
| EP1578777B1 (en) | 2002-07-15 | 2008-11-26 | The Trustees of Princeton University | Iap binding compounds |
| JP2006514096A (ja) | 2002-11-27 | 2006-04-27 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 癌細胞においてアポトーシスを誘導するための方法および組成物 |
| US20040180828A1 (en) | 2003-01-30 | 2004-09-16 | Yigong Shi | Caspase-9 : BIR domain of XIAP complexes and methods of use |
| CN1933847A (zh) | 2004-01-16 | 2007-03-21 | 密歇根大学董事会 | Smac肽模拟物及其应用 |
| CA2552937A1 (en) | 2004-02-05 | 2005-08-18 | Novartis Ag | Combination of (a) a dna topoisomerase inhibitor and (b) an iap inhibitor |
| US7309792B2 (en) | 2004-03-01 | 2007-12-18 | Board Of Regents, The University Of Texas System | Dimeric small molecule potentiators of apoptosis |
| AU2005228950B2 (en) | 2004-03-23 | 2012-02-02 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
| ES2394441T3 (es) | 2004-04-07 | 2013-01-31 | Novartis Ag | Inhibidores de IAP |
| DK1778718T3 (da) * | 2004-07-02 | 2014-11-10 | Genentech Inc | Iap-inhibitorer |
| US7674787B2 (en) | 2004-07-09 | 2010-03-09 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| EP2457895A1 (en) | 2004-07-12 | 2012-05-30 | Idun Pharmaceuticals, Inc. | Tetrapeptide analogs |
| JP5230865B2 (ja) | 2004-07-15 | 2013-07-10 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ結合性化合物 |
| ES2349110T5 (es) | 2004-12-20 | 2013-11-27 | Genentech, Inc. | Inhibidores de IAP derivados de pirrolidina |
| CN103083644B (zh) | 2005-02-25 | 2014-05-28 | 泰特拉洛吉克药业公司 | Iap二聚体抑制剂 |
| US20070003535A1 (en) | 2005-03-17 | 2007-01-04 | Reed John C | Methods and compositions for derepression of IAP-inhibited caspase |
| DE102005017116A1 (de) | 2005-04-13 | 2006-10-26 | Novartis Ag | Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP) |
| EP1883627B1 (en) | 2005-05-18 | 2018-04-18 | Pharmascience Inc. | Bir domain binding compounds |
| WO2006128455A2 (en) | 2005-05-25 | 2006-12-07 | 2Curex Aps | Compounds modifying apoptosis |
| MX2007015419A (es) | 2005-06-08 | 2008-02-21 | Novartis Ag | Compuestos organicos. |
| CA2617642A1 (en) * | 2005-08-09 | 2007-02-22 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
| CA2564872C (en) | 2005-10-25 | 2010-12-21 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| RU2451025C2 (ru) | 2005-12-19 | 2012-05-20 | Дженентек, Инк. | Ингибиторы iap |
| AU2006331964A1 (en) | 2005-12-20 | 2007-07-05 | Novartis Ag | Combination of an IAP-inhibitor and a taxane7 |
| WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| MX2008012053A (es) | 2006-03-21 | 2008-12-17 | Joyant Pharmaceuticals Inc | Promotores de apoptosis de molecula pequeña. |
| SI2019671T1 (sl) | 2006-05-05 | 2015-03-31 | The Regents Of The University Of Michigan | Intermediati za pripravo bivalentnih Smac-mimetikov |
| SG171682A1 (en) | 2006-05-16 | 2011-06-29 | Aegera Therapeutics Inc | Iap bir domain binding compounds |
| US20100144650A1 (en) | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| WO2008014238A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| AR064235A1 (es) | 2006-07-24 | 2009-03-25 | Tetralogic Pharmaceuticals Cor | Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer |
| EP2049563B1 (en) | 2006-07-24 | 2014-03-12 | Tetralogic Pharmaceuticals Corporation | Dimeric iap antagonists |
| US20100056495A1 (en) | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| WO2008014240A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| PE20110220A1 (es) | 2006-08-02 | 2011-04-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| JP5190062B2 (ja) | 2006-10-12 | 2013-04-24 | ノバルティス アーゲー | Ｉａｐ阻害剤としてのピロリジン誘導体 |
| JP2010507096A (ja) | 2006-10-19 | 2010-03-04 | ノバルティス アーゲー | 有機化合物 |
| PT2089024E (pt) | 2006-11-28 | 2011-08-31 | Novartis Ag | Combinação de inibidores de iap e inibidores de flt3 |
| KR20090083412A (ko) | 2006-11-28 | 2009-08-03 | 노파르티스 아게 | 급성 골수성 백혈병의 치료를 위한 ｉａｐ 억제제의 용도 |
| WO2008073306A1 (en) | 2006-12-07 | 2008-06-19 | Novartis Ag | Organic compounds |
| US8063218B2 (en) | 2006-12-19 | 2011-11-22 | Genentech, Inc. | Imidazopyridine inhibitors of IAP |
| CA2684169C (en) | 2007-04-12 | 2012-06-19 | Joyant Pharmaceuticals, Inc. | Smac mimetic dimers and trimers useful as anti-cancer agents |
| SI2139490T1 (sl) | 2007-04-13 | 2014-11-28 | The Regents Of The University Of Mchigan Office Of Technology Transfer, University Of Michigan | Diazo bicikliäśni smac mimeti in njih uporaba |
| AU2008245447C1 (en) | 2007-04-30 | 2014-11-20 | Genentech, Inc. | Inhibitors of IAP |
| US20100203012A1 (en) | 2007-05-30 | 2010-08-12 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
| EP2058312A1 (en) | 2007-11-09 | 2009-05-13 | Universita' degli Studi di Milano | SMAC mimetic compounds as apoptosis inducers |
| US20110117081A1 (en) | 2008-05-05 | 2011-05-19 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
| JP5779091B2 (ja) | 2008-05-16 | 2015-09-16 | ノバルティス アーゲー | Ｉａｐ阻害剤による免疫調節 |
| TW201011006A (en) | 2008-06-16 | 2010-03-16 | Nuevolution As | IAP binding compounds |
| US20110171171A1 (en) | 2008-06-27 | 2011-07-14 | Aegera Therapeutics, Inc. | Bridged secondary amines and use thereof as iap bir domain binding compounds |
| EP2318395A4 (en) | 2008-08-02 | 2011-10-26 | Genentech Inc | IPA INHIBITORS |
| WO2010015090A1 (en) | 2008-08-07 | 2010-02-11 | Aegera Therapeutics Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
| US8399683B2 (en) | 2008-09-17 | 2013-03-19 | Tetralogic Pharmaceuticals | IAP inhibitors |
| US20110177060A1 (en) | 2008-09-19 | 2011-07-21 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
-
2006
- 2006-10-20 CA CA2564872A patent/CA2564872C/en not_active Expired - Fee Related
- 2006-10-20 RU RU2008120408/04A patent/RU2418807C2/ru not_active IP Right Cessation
- 2006-10-20 US US11/583,816 patent/US7589118B2/en not_active Expired - Fee Related
- 2006-10-20 EP EP06790872A patent/EP1951698A4/en not_active Withdrawn
- 2006-10-20 WO PCT/CA2006/001721 patent/WO2007048224A1/en not_active Ceased
- 2006-10-20 KR KR1020087012374A patent/KR20080067357A/ko not_active Withdrawn
- 2006-10-20 AU AU2006308453A patent/AU2006308453B9/en not_active Ceased
- 2006-10-20 BR BRPI0617751-4A patent/BRPI0617751A2/pt not_active IP Right Cessation
- 2006-10-20 JP JP2008536890A patent/JP2009512719A/ja active Pending
- 2006-12-01 US US11/606,883 patent/US7547724B2/en not_active Expired - Fee Related
- 2006-12-04 US US11/607,998 patent/US7795298B2/en not_active Expired - Fee Related
- 2006-12-04 US US11/607,964 patent/US8063095B2/en not_active Expired - Fee Related
-
2008
- 2008-04-17 IL IL190936A patent/IL190936A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009512719A5 (enExample) | ||
| JP2009529544A5 (enExample) | ||
| JP2019537570A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| RU2008120408A (ru) | Соединения, связывающие bir домены iap | |
| JP2020516621A5 (enExample) | ||
| JP2017528488A5 (enExample) | ||
| JP2017528524A5 (enExample) | ||
| US20090054415A1 (en) | Combinations, methods and compositions for treating cancer | |
| JP2009537461A5 (enExample) | ||
| RU2007132181A (ru) | ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ | |
| JP2014132009A5 (enExample) | ||
| JP2017504611A (ja) | 組合せ医薬 | |
| RU2017109912A (ru) | Лечение антителами против vegf | |
| JP2019501197A5 (ja) | 腫瘍を処置するための抗ｈｅｒ２組み合わせ | |
| Winer et al. | A review of omacetaxine: a chronic myeloid leukemia treatment resurrected | |
| JP2019501196A5 (ja) | 腫瘍を処置するための抗ｃｄ２０組み合わせ | |
| JP2017526677A5 (enExample) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| RU2018128796A (ru) | Противоопухолевое средство, содержащее иммуномодулятор и усилитель противоопухолевого эффекта | |
| CN103327977A (zh) | 恶液质的治疗或预防剂 | |
| RU2014115290A (ru) | Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов | |
| JP2019501879A5 (enExample) | ||
| JP2014533277A5 (enExample) | ||
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト |